The Strategic Timing of AntiRetroviral Treatment (START) trial, in people with CD4 counts of more than 500 cells per μL and who were naive to antiretroviral therapy (ART), revealed a 57% reduction in risk of AIDS and non-AIDS morbidity and mortality in participants randomly assigned to immediate ART initiation compared with those allocated to deferred initiation.1 Here, CD4 is linked to AIDS.